In specific reference to Her2+ BC, in a prior retrospective study, we investigated the association of TAZ with pathologic complete response (pCR) in 61 Her2+ BC patients following exposure to neoadjuvant chemotherapy plus trastuzumab. This evidence concerns the gene ERBB2 and breast cancer.